Compare WTBA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTBA | AGEN |
|---|---|---|
| Founded | 1893 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.6M | 147.4M |
| IPO Year | 2002 | 1999 |
| Metric | WTBA | AGEN |
|---|---|---|
| Price | $23.97 | $3.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.00 | $14.50 |
| AVG Volume (30 Days) | 26.1K | ★ 744.4K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | 35.21 | ★ 100.00 |
| EPS | 0.61 | ★ 1.02 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $23.80 | $107.63 |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $39.20 | ★ $3.32 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $17.50 | $2.71 |
| 52 Week High | $26.60 | $7.34 |
| Indicator | WTBA | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 48.00 |
| Support Level | $23.49 | $2.93 |
| Resistance Level | $24.25 | $4.72 |
| Average True Range (ATR) | 0.50 | 0.24 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 90.85 | 68.46 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings, and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.